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Abstract
Manganese is essential to life, and humans typically absorb sufficient quantities of this ele-
ment from a normal healthy diet; however, chronic, elevated ingestion or inhalation of man-
ganese can be neurotoxic, potentially leading to manganism. Although imaging of large
amounts of accumulated Mn(II) is possible by MRI, quantitative measurement of the biodis-
tribution of manganese, particularly at the trace level, can be challenging. In this study, we
produced the positron-emitting radionuclide 52Mn (t1/2 = 5.6 d) by proton bombardment
(Ep<15 MeV) of chromium metal, followed by solid-phase isolation by cation-exchange chro-
matography. An aqueous solution of [52Mn]MnCl2 was nebulized into a closed chamber with
openings through which mice inhaled the aerosol, and a separate cohort of mice received
intravenous (IV) injections of [52Mn]MnCl2. Ex vivo biodistribution was performed at 1 h and
1 d post-injection/inhalation (p.i.). In both trials, we observed uptake in lungs and thyroid
at 1 d p.i. Manganese is known to cross the blood-brain barrier, as confirmed in our studies
following IV injection (0.86%ID/g, 1 d p.i.) and following inhalation of aerosol, (0.31%ID/g, 1 d
p.i.). Uptake in salivary gland and pancreas were observed at 1 d p.i. (0.5 and 0.8%ID/g), but to
a much greater degree from IV injection (6.8 and 10%ID/g). In a separate study, mice received
IV injection of an imaging dose of [52Mn]MnCl2, followed by in vivo imaging by positron emis-
sion tomography (PET) and ex vivo biodistribution. The results from this study supported many
of the results from the biodistribution-only studies. In this work, we have confirmed results in
the literature and contributed new results for the biodistribution of inhaled radiomanganese for
several organs. Our results could serve as supporting information for environmental and occu-
pational regulations, for designing PET studies utilizing 52Mn, and/or for predicting the biodistri-
bution of manganese-based MR contrast agents.
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Introduction
Manganese is a micronutrient that is essential for human life in only trace amounts [1, 2], but
deficiency is rare [3]. Existing primarily in the Mn(IV) oxidation state in the earth’s crust [4],
manganese is the third most abundant transition metal in the crust [4] and is taken up by
plants, where it is utilized in green leaves as an oxidizer in photosynthesis [4]. Manganese(II)
is by far the most electrochemically stable oxidation state for manganese [4] and the state that
is predominantly used as an enzymatic cofactor. Manganese in the blood is found as Mn(III)
bound to binding sites for Fe(III) on transferrin [5, 6] or as Mn(II) bound to other serum pro-
teins [7], but the vast majority of manganese leaves the blood quickly and is accumulated in
various organs or excreted [8]. The necessity of manganese as a nutrient is sometimes over-
shadowed by its neurotoxic effects that can result in manganism [2], a condition that was first
described in 1837 [9]. In mangansim, early-stage patients often present with psychiatric symp-
toms [10, 11] that are sometimes referred to as “manganese madness” [12]. Later-stage patients
develop symptoms of parkinsonism, including intellectual impairment, tremors, and rigidity
similar to idiopathic Parkinson’s disease [9, 12–14], with a few key differences [12].
In addition to studying the neurotoxicity of manganese, an additional motivation for
understanding the biodistribution of free manganese is that Mn(II) can be utilized in contrast
agents for manganese-enhanced magnetic resonance imaging (MEMRI), which was studied
early in the history of MRI by P. Lauterbur and colleagues [15] and later achieved in vivo [16].
Manganese(II) is “high-spin” from its five unpaired valence electrons, which shorten the spin-
lattice time constant (T1) for nearby 1H nuclei, resulting in brighter signal (when using a T1-
weighted MR pulse sequence) [8, 17–19]. In fact, T1-weighted MRI may be used as an indicator
of manganese-induced parkinsonism [20, 21]. Additionally, chelated Mn(II) could serve as an
alternative to Gd(III), which is currently the most commonly used cation core in T1-shorten-
ing contrast agents for MRI, since free Gd(III) is excreted through the kidneys, but free Mn(II)
is excreted almost exclusively in feces, primarily from bile from the liver [22–25].
Thus far, the only manganese-based MR contrast agent to reach the market in the United
States was Teslascan1 (mangafodipir, manganese(II)-dipyridoxyl diphosphate, Mn-DPDP)
(Amersham plc, Amersham, Buckinghamshire, United Kingdom), a chelated form of Mn(II)
that reduces cardiac toxicity, by slowing the availability of free Mn(II) [17, 26–28] due to disso-
ciation [29]. Mn-DPDP was officially indicated for detecting liver metastases of colorectal can-
cer [26, 27], but it no longer on the market in the United States. Various other chelated forms
of Mn(II) and Mn(III) [30] are being developed, numerous kinds of Mn-doped inorganic and
organic nanoparticles are in the in vitro and pre-clinical stages [19], and oral administration of
liquids containing Mn(II) has even been tested in humans [31, 32]. However, since MRI is not
inherently as quantitative as PET, it is valuable to develop surrogates that are radiolabeled with
a positron-emitting radioisotope of manganese [27, 28, 33, 34] for quantitative confirmation of
their biodistribution.
Although imaging of large amounts of accumulated Mn(II) is possible by T1-weighted MRI,
true quantification of the biodistribution of non-radioactive manganese in vivo is difficult.
However, pre-clinical imaging and ex vivo biodistribution using tracer amounts of radioman-
ganese can provide a route to quantify the amount of manganese as a percentage of adminis-
tered dose in animal models. Past studies have examined the biodistribution of manganese in
various forms administered by various routes, mostly in rodents, and have generally found
that manganese is distributed to many tissues throughout the body. Several of these studies
have used the radiotracers 52Mn (t1/2 = 5.6 d [35]), and 54Mn (t1/2 = 312 d [35]), or by adminis-
tering stable manganese (55Mn: 100% natural abundance [35]) followed by various techniques
for quantifying non-radioactive metals in the tissues [17, 36–38]. More recently, researchers at
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the University of Wisconsin have published results for ex vivo biodistribution of IV 52Mn(II)
in rodents: Graves, et al. [39] have investigated biodistribution in tumor-bearing mice at 96 h
post-injection (p.i.), as well as by in vivo PET at timepoints 4–96 h p.i. Additionally, Brunn-
quell, et al. [40] have investigated biodistribution in rats at 4 and 48 h p.i.
The half-life of 52Mn is long enough for in vivo imaging at timepoints as long as days or
even weeks p.i., and 52Mn emits positrons at a sufficient branching ratio (Iβ+ = 29.6% [35]) for
in vivo medical imaging by positron emission tomography (PET). Manganese-52 provides the
additional benefit of low-energy positron emission (Eβ+ = 242 keV [35]) (resulting in better
spatial resolution in PET). Manganese-52 can be produced efficiently by the 52Cr(p,n) or natCr
(p,x) reactions (52Cr: 83.8% natural abundance) by bombarding target material with low-
energy protons (6<Ep<20 MeV [41, 42]). Thus, 52Mn can be produced at medical centers
using protons from a low-energy cyclotron without expensive isotopically enriched target
material. So far, 52Mn has been used in several ex vivo and in vivo studies, including the biodis-
tribution of Mn(II) [43], cell tracking [44], antibody imaging [39], and as a positron-emitting
surrogate of a MEMRI contrast agent [34].
In this work, we utilized the radioisotope 52Mn to study the biodistribution of free Mn(II) in
sixteen different tissues in mice following intravenous injection or inhalation in saline solution.
Materials and methods
Materials
Copper sheet (0.762 mm thick, 99.9% purity) was purchased from ESPI Metals (Ashland, Ore-
gon, United States), and natural abundance chromium was electroplated by Four Star Finish-
ing (Saint Louis, Missouri, United States). Nitrogen (N2) gas was purchased from Cee Kay
Supply (Saint Louis), and all other chemicals were purchased from Sigma-Aldrich (Saint
Louis), unless otherwise indicated.
Production of 52Mn
Manganese-52 was produced from the natCr(p,x) reaction using the CS-15 cyclotron at Wash-
ington University School of Medicine in Saint Louis as previously reported [41, 42]). We
developed a method for fabricating batches of thin chromium foils that would fit into our tar-
get holders [41], similar to the one used by Tanaka and Furukawa [45]. Non-enriched chro-
mium was electroplated onto copper metal sheet in an industrial “hard chrome” electroplating
bath (Four Star Finishing, Saint Louis, United States). Following electroplating, the copper
backing was removed by repeatedly digesting it in diluted nitric acid in a large glass pan, even-
tually leaving the electrodeposited layer of chromium as a batch of thin metal foils [41, 45]. In
previously published results [41], the only contaminants >100 ppm (within uncertainty) were
Sn (1195 ppm) and Se (134 ppm) in the final product. These elemental impurities were discov-
ered by ICP-MS in a dissolved chromium foil that was never irradiated but was produced in a
similar manner to the foils used in this work. For each production of 52Mn, one or more foils
of this chromium metal was placed in a target holder and bombarded with protons from the
CS-15 cyclotron (The Cyclotron Corporation, Berkeley, California, United States) [41].
Gamma-ray spectroscopy results from a non-dissolved chromium foil from a previous bom-
bardment showed a radionuclidic purity of>99.5% (activity%) 52Mn (<0.5% 54Mn).
Several separation procedures have been published for 52Mn from a chromium metal tar-
get [39, 43, 46–52]. Following a method published by Buchholz, et al. in 2013 [50], cation-
exchange chromatography was used to separate 52Mn from the chromium metal target after
proton bombardment. The irradiated chromium metal was dissolved in diluted hydrochloric
acid (for the biodistribution-only study: 5.5 mL of 1:10 (v/v) c. HCl:H2O). The solution was
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repeatedly evaporated and resuspended in sulfuric acid to replace the chloride anions with sul-
fate, then diluted to ~0.1 M sulfuric acid. Next, the solution was transferred to a simple grav-
ity-flow column (inner diameter = 1.0 cm) consisting of AG 50W-X8 cation-exchange resin
(Bio-Rad, Hercules, California, United States) that was pre-conditioned in 0.1 M sulfuric acid.
The majority of the Cr(III) passed through the column and was further eluted in 0.1 M sulfuric
acid, while 52Mn(II) was immobilized on the column. Of the 52Mn that was measured in the
top chromium foil,>90.9% was eluted in 6 M HCl. The resulting solution was brought to dry-
ness using heat and/or (N2) gas, and redissolved in saline. If necessary, solutions of hydrochlo-
ric acid, sodium hydroxide, and/or ammonium hydroxide were added to adjust the pH of the
resuspended saline product to pH 4.0–5.0. When manganese is dissolved in HCl, it is expected
to form manganese(II) chloride, which is soluble in water; manganese(IV) is much less soluble
in water, and we did not observe any insolubility of our radiomanganese. For the inhalation
study, the final solution that was placed inside the nebulizer was between 13.1–13.3 MBq
(355–360 μCi) in 600 μL. The isotonicity of both the IV and inhaled doses was not evaluated in
the current study, so it is possible that the concentrations of metal cation contaminants were
great enough to influence the pharmacokinetics of the 52Mn(II). Metal impurities in our 52Mn
will be addressed in future studies.
Administration of 52Mn
All animals were purchased from Charles River Laboratories (Wilmington, Massachusetts,
United States) and allowed to eat and drink ad libitum. All experiments involving animal sub-
jects were performed under a protocol that was approved by the Animal Studies Committee of
Washington University in St. Louis. Male CD-1 mice were used for biodistribution studies for
IV injection and aerosol inhalation.
For the cohorts that received IV injection, mice (n = 4) were anesthetized by inhalation of
isoflurane in a chamber before each mouse was removed and injected in the tail vein with
~100 μL volume, ~0.2–0.4 MBq (~5–10 μCi) of 52Mn. One extra syringe was prepared as a
standard for later determining the count rate per volume of injectate using the gamma counter
(see below). Each syringe, including the standard syringe, was weighed pre- and post-injection
to determine the mass of injectate that was actually expelled.
In the inhalation studies, doses of 52Mn salt solutions were administered to mice as previ-
ously reported by our research group [53, 54] for other radiolabeled compounds. Solutions
were loaded into a Small Volumetric Mean Diameter (VMD) Nebulizer Unit (Aeroneb Lab,
Aerogen, Dangan, Galway, Ireland) with the following specifications: >0.1 mLmin-1 flow rate,
4.0–6.0 μm VMD, <0.2 mL residual volume. The exit port of the nebulizer was inserted into a
clear plastic chamber (20.3×20.3×11.4 cm l×w×h). Four mice for each timepoint were inserted
individually, without any anesthesia, into four tubes with a plastic plunger to gently push the
body to the front of the tube and snout through a small opening at the opposite end of the
tube. The 52Mn solution was pipetted into the liquid reservoir of the nebulizer and then the
nebulizer was powered on, producing an aerosol that filled the chamber. The four mice were
allowed to inhale the aerosol for ~4–7 min., then the tubes were detached, and the mice were
removed. One of the mice from each inhalation group of four mice was euthanized immedi-
ately following removal from its tube to serve as the standard “dose mouse” for the dose
received by that group, leaving three mice alive from each administration by inhalation.
Ex vivo biodistribution
At each timepoint post-administration (by injection or inhalation), animals were euthanized,
dissected, and then each tissue was weighed and analyzed for radioactivity using a sodium
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iodide gamma-ray counter (Beckman 8000, Beckman Instruments, Irvine, California, United
States). For the injection study, the injectate from the standard syringe was diluted, and one
unique aliquot of this dilution was assayed after the tissues from each animal. For the inhala-
tion study, the whole carcass of the “dose mouse” from each inhalation group was assayed
once by the gamma counter. For the samples from each administration route, a single back-
ground measurement was performed, and the count rate (counts per minute, CPM) from each
sample of tissue (or of diluted standard) was corrected by background subtraction and by
decay correction (neglecting decay during gamma counting). The corrected CPM from the
diluted standard was used to estimate the (corrected) CPM from the same mass of undiluted
standard. The corrected CPM from each tissue sample was normalized both to the mass of the
tissue sample (in grams, g) and to the estimated CPM from the mass of undiluted injectate that
was actually delivered to the corresponding animal (injected dose, ID). Thus, the relative con-
centration of 52Mn in each tissue sample was calculated as %ID/g.
Statistical and uncertainty analysis
For each tissue and timepoint, results were averaged across animals—n = 4 in the injection
study and n = 3 in the inhalation study—and statistical analysis was performed. The uncer-
tainty in the final result for each tissue reflects only sample standard deviation across animals
for that tissue. Statistical significance between the biodistribution at 1 d after injection or inha-
lation was determined using Welch’s t-test, which is a correction to Student’s t-test that is
applied when performing a hypothesis test on sample means from two unpaired samples of
different size and variance, as was the case in this comparison. This test was administered
using the TTEST function in Microsoft Excel for Mac (various versions, Microsoft, Redmond,
Washington, United States) for a two-tailed t-test between two samples of heteroscedastic
(unequal variance) data.
Results
For the biodistribution-only study, bombardment of natCr metal foils with ~13.4 MeV pro-
tons for a total of 27 μAh (12 μA), which produced 41 MBq (1.1 mCi) (decay-corrected to
end-of-bombardment), which was 69.6% of theoretical yield based on our published cross-
section results [41]. Fig 1 and Table 1 show the results from ex vivo biodistribution of 52Mn
in saline administered via intravenous injection or by inhalation. Manganese-52 was cleared
Fig 1. Plot showing results from ex vivo biodistribution of saline solutions containing 52Mn
administered via intravenous injection or inhalation. The timepoints shown represent the time after
administration of the dose. Results for the p-values from Student’s t-test with Welch’s correction at 1 d p.i.
only: *: p<5%; **: p<0.1%; ***: p<0.01%; -: p5%. Sample sizes for each timepoint were n = 4 mice for
injection and n = 3 for inhalation. Uncertainties: one absolute standard deviation in units of %ID/g. Error bars
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rapidly from the blood, as demonstrated by its rapid decrease from 1 h to 1 d p.i., and the
activity in the gastrointestinal tract—stomach and intestines—also decreased rapidly
between these timepoints. At 1 h p.i., the highest activity was found, in decreasing order, in
the liver, kidney, lung, heart, pancreas, spleen, and salivary glands (Table 1); however, by 1
d p.i., the concentration of 52Mn in all of these organs of high initial uptake had decreased
substantially, except for the salivary glands, pancreas, and kidney, as shown in Fig 1. Among
the other tissues, which had lower uptake at 1 h p.i., 52Mn was retained to various degrees in
the brain, bone, and thyroid.
Comparing the biodistribution of 52Mn(II) at 1 d after IV injection or inhalation, we
considered two sample means to be statistically significant if the p-value from the t-test
was <0.05. Applying the t-test and this cutoff value, nearly all tissues that we measured
showed a statistically significant difference, with the exception of brain, thyroid, and stom-
ach, all of which demonstrated large relative sample standard deviations (%RSD). Salivary
glands and muscles demonstrated especially strong statistical significance (p<0.0001). S1
Fig (Supplementary Information) shows co-registered PET/CT images of two mice (spe-
cies: C57-Black-6) from a separate but similar study in which larger doses of [52Mn]MnCl2
were administered for in vivo PET imaging. These images demonstrate a distribution of
PET signal in many of the same tissues with high uptake in the current ex vivo biodistribu-
tion results, and these images suggest the potential utility of 52Mn for further quantitative
PET/CT studies.
Table 1. Results from ex vivo biodistribution of saline solutions containing 52Mn administered via intravenous injection or inhalation.
Uptake of 52Mn (%ID/g) t-test (p)
Intravenous Inhalation
1 h 1 d 1 h 1 d 1 d
Blood 1.3 ± 0.2 0.10±0.02 0.019±0.008 0.007±0.003 0.0011
Lung 11 ± 3 4.5±0.4 16±5 18±4 0.026
Liver 20 ± 2 12±1 0.39±0.09 0.7±0.2 0.00013
Spleen 9 ± 3 3.3±0.3 0.07±0.03 0.12±0.05 0.00025
Kidney 18 ± 2 17±2 0.31±0.09 2.0±0.7 0.00012
Muscle 1.4 ± 0.2 1.13±0.09 0.14±0.05 0.04±0.03 0.000028
Heart 10 ± 2 2.9±0.4 0.3±0.1 0.23±0.08 0.020
Brain 0.8±0.1 0.9±0.1 0.09±0.07 0.3±0.4 0.00034
Bone 2.90±0.08 2.6±0.3 0.1±0.2 0.11±0.03 0.14
Thyroid 3±1 2.2±0.7 6±4 6±3 0.00026
Pancreas 9±1 10±3 0.25±0.02 0.8±0.4 0.17
Stomach 2.1±0.6 1.4±0.5 21±6 2±1 0.0073
Whole Intestine 4.2±0.6 1.51±0.06 20±3 3.6±0.7 0.00029
Salivary Gland 6.7±0.8 6.8±0.6 1.2±0.2 0.5±0.2 0.29
Fat 0.58±0.09 0.4±0.2 0.2±0.2 0.004±0.001 0.031
Thymus 1.3±0.2 0.9±0.1 1±1 0.1±0.1 0.000074
The timepoints shown represent time after administration of the dose. Sample sizes for each timepoint were n = 4 mice for injection and n = 3 for inhalation.
Uncertainties: one absolute standard deviation in units of %ID/g (i.e., percentage does not imply relative sample standard deviation). All values for
uncertainty were rounded to one significant digit, and the mean value was rounded to a matching number of decimal places. Results for the p-values from
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Discussion
For the comparison of IV injection to inhalation of 52Mn in mice, the concentration of 52Mn
in most tissues at both 1 h and 1 d timepoints is higher than in the inhalation results. The activ-
ity in the gastrointestinal tract was much greater in the inhalation results, suggesting that some
of the dose may have been swallowed directly from the aerosol or inhaled, cleared by mucocili-
ary clearance, and then swallowed. Also in our studies, we observed uptake in the pancreas
and brain, while 52Mn that entered the stomach or intestines did not appear to be retained,
although the one hour amounts were much higher in the inhalation groups likely due to puta-
tive swallowing of some of the dose. Retention of 52Mn in the brain, thyroid, and thymus was
observed in results from both injection and inhalation. We also found significant uptake of
52Mn at 1 d in the bone (2.6%ID/g) resulting from injection, but not from inhalation.
For both injection and inhalation, 52Mn was cleared rapidly from the blood, and the injec-
tion data showed 52Mn in the liver and kidney in <1 h. The inhalation data also suggest accu-
mulation in the liver and kidneys, but this accumulation took much longer than one hour.
Although manganese appears to accumulate in both liver and kidneys, results from the litera-
ture [22–25] suggest that very little manganese is excreted in urine. Instead, the vast majority
of manganese is excreted in feces, primarily due to release of manganese from the liver into the
enterohepatic circulation. In other studies, animals that were administered manganese or
radiomanganese intravenously [17, 22, 55–58], high uptake was generally observed in the kid-
ney, pancreas, liver, adrenal glands, and intestine, as well as comparatively small amounts in
the brain. For intratracheal instillation, Heilig, et al. [59] and Brain, et al. [60] reported that
[54Mn]MnCl2 was retained in the lungs to large extent, but was also found in significant
amounts in the intestines, liver, kidneys, and in small amounts in the brain. These intratracheal
instillation studies also showed that Mn can enter the bloodstream from the lungs, possibly by
ion channels, but not by the divalent metal transporter-1 (DMT-1) in that particular tissue [59,
60]. These general trends in manganese distribution agree with studies that focused more nar-
rowly on the in vitro or in vivo uptake of manganese by cells or tissues that included liver [25,
61], kidney [61], pancreas [61], intestines [60, 62], salivary glands [17, 63], myocardium [58],
and bone [64].
Owing to its neurotoxic effects, particular interest has been paid to uptake of manganese in
the brain by various routes. Kanayama, et al. [65] administered to mice by eight different
routes a solution containing sixteen different radiotracers, mostly transition metals, and, for
most administration routes, 54Mn(II) had higher brain uptake than most of the other tracers.
In several other studies, rodents received radiomanganese by carotid injection or continuous
in situ brain perfusion brain. These studies suggest that manganese enters the brain by more
than one mechanism, including carrier-mediated uptake of Mn-citrate [66], by store-operated
calcium channels as Mn(II) [67], by transferrin-receptor mediated endocytosis as Mn-transfer-
rin [68, 69], or by other unspecified mechanism(s) that are faster than simple diffusion [69,
70]. In a comparison of 54Mn species administered by in situ brain perfusion, Mn-citrate was
transported across the blood-brain barrier faster than either free Mn(II) or Mn-transferrin,
suggesting that Mn-citrate might be an important route for manganese uptake in the brain
[66]. Furthermore, it is likely that manganese accumulates in the brain because it effluxes at a
rate that is consistent with simple diffusion [71, 72].
Since certain inhaled substances can enter the brain directly from the olfactory bulb—with-
out entering the bloodstream—there have been a considerable number of studies examining
the possibility of manganese entering the brain by such mechanisms. Characterization of this
mechanism(s) would be particularly relevant to the problem of inhaled manganese in metal
workers. Animal studies using radiomanganese [73, 74] or MEMRI [75, 76], suggested that
Biodistribution of Manganese-52
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Mn(II) can be transported from the olfactory bulb and into olfactory neurons, transported
through those neurons, across synaptic junctions, into secondary olfactory neurons, and then
into the diencephalon and cerebrum, and (in rats) into the spinal cord. Thompson, et al. [77]
tested uptake in rats with defective divalent metal transporter-1 (DMT-1) proteins and con-
firmed that this transporter is involved in manganese uptake in the rat olfactory bulb based on
higher uptake in healthy control rats. In rats, ninety minute nose-only inhalation of aerosol-
ized [54Mn]MnCl2 [78] or [
54Mn]MnHPO4 [79] solution leads to uptake in the olfactory bulb
and olfactory tubercle. In both studies, they observed uptake in lungs, liver, kidney, and pan-
creas, and—at much lower amounts—in the striatum of the brain. In a similar study, Lewis,
et al. [38] exposed mice and rats to nebulized, non-radioactive MnCl2 for 10 nose-only doses
of 6 hours each. Sample analysis by proton induced X-ray emission (PIXE) revealed elevated
manganese in trigeminal ganglia, suggesting this nerve as a possible pathway for brain entry of
manganese. Along with these published examples of brain uptake of Mn cations, the present
study has shown uptake of 52Mn(II) in the mouse brain following administration by IV injec-
tion or inhalation or aerosol. The magnitude of uptake in the brain that we observed was low
compared to some other tissues, with uptake being greater following IV injection than from
inhalation. However, the presence of an exogenous substance in the brain in any amount dem-
onstrates an ability to cross the blood-brain barrier, which is an important result in itself.
In our studies, relatively high uptake was observed in the lung and thyroid following either
route of administration. Although several papers confirmed thyroid uptake of manganese
from different administration routes in animal models [80–83], the biology of uptake of man-
ganese in the thyroid does not seem clear [83]. Interestingly, electron spin resonance (ESR)
has shown that only a small fraction of the manganese naturally found in the rat thyroid is in
the 2+ oxidation state [37], perhaps suggesting that it is bound to serum protein(s) as Mn(III)
and not present as a free Mn(II). Additionally, following subcutaneous injection of Mn(II)Cl2,
in guinea pigs [81], manganese rapidly accumulated in thyroid by 1 d p.i., but then 70% of the
manganese in the thyroid at 1 d had cleared by 2 d p.i.; and then 85%, by 96 hours p.i. Inhaled
manganese uptake in salivary glands was in agreement with observations in welders exposed
to manganese [84]. Interestingly, our results showed that injection of [52Mn]MnCl2 exhibited
higher and faster uptake in salivary gland than in the inhalation study. Our results demonstrate
uptake of 52Mn in the brain, thyroid, and pancreas in all trials. Interestingly, uptake from IV
administration was higher in brain and pancreas, but lower in thyroid, compared to inhalation
results. Importantly, Graves, et al. [85] have shown that anesthesia by isoflurane can signifi-
cantly decrease uptake of Mn(II) in the pancreas in fasted mice. This study concluded that iso-
flurane initiates a sequence in pancreatic β-cells that reduces opening of voltage-dependent
calcium channels (VDCCs)—the channels through which Ca(II), Mn(II), and potentially other
divalent cations can enter the pancreatic beta cells. In one part of this work, 52Mn(II) in aque-
ous sodium acetate was administered IV with and without anesthesia by isoflurane, and the
uptake in the pancreas at 1 h p.i. under anesthesia was similar to our result (in %ID/g). How-
ever, the uptake in the pancreas without anesthesia was ~3x greater than with anesthesia. Since
our study only used anesthesia during IV administration of 52Mn(II), and not during inhala-
tion, we expect that in the absence of anesthesia in both routes of administration the difference
would be even greater in uptake in the pancreas between IV injection and inhalation.
Along with recently renewed interest in manganese for signal in both MRI and PET,
Brunnquell, et al. [40] have published results for brain uptake of manganese in female rats fol-
lowing tail vein infusion at 2 mL/h of non-carrier-added 52Mn(II) in radiotracer concentra-
tions. In addition to monitoring brain uptake of 52Mn(II), this study included results for
biodistribution from several tissues at 4 and 48 h p.i. Compared to Brunnquell, et al., our bio-
distribution results were roughly 10x greater for many tissues (in %ID/g), likely due to a
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roughly 10x lower body mass of the mice in our study compared to rats, along with different
timepoints and gender. However, the relative changes from 4 to 48 h p.i. in this study was simi-
lar to our results at 1 h and 1 d, including brain, spleen, liver, intestine, heart, lung, and muscle,
while results for blood, pancreas, thymus, kidney, and bone demonstrated results that were
less similar to our results, based on tissue concentrations relative to other tissues and/or rela-
tive changes from 4 to 48 h. Manganese-52 might someday be used as a PET agent for niche
clinical research applications, but our biodistribution results in mice can be used, in conjunc-
tion with other published results, to inform regulations for safe levels of environmental and
occupational exposure to manganese. The primary objective of this work was to contribute to
basic research with regards to the in vivo behavior of manganese cations, which are increas-
ingly being studied preclinically for PET agents and MRI contrast agents—with only the possi-
bility for future translation to the clinic.
Conclusion
In this work, we have produced 52Mn via the natCr(p,x) reaction, chemically isolated this radio-
isotope of manganese from the chromium metal target material, and reported new data for
the biodistribution of manganese in mice following administration by IV injection or inhala-
tion. Manganese-52 was produced by cyclotron bombardment with low-energy protons on
chromium metal, and subsequent chemical separation of 52Mn(II) was performed by cation-
exchange chromatography and re-dissolved in saline solution for ex vivo biodistribution stud-
ies in mice. The doses were administered by IV injection or inhalation, always resulting in
uptake of 52Mn in the brain, thyroid, and pancreas. Interestingly, uptake from IV administra-
tion was higher in brain and pancreas, but lower in thyroid, compared to inhalation results.
While 52Mn might find use as a PET agent in preclinical studies, our biodistribution results in
mice may be used to inform regulations for safe levels of environmental and occupational
exposure to Mn(II) and the predicted biodistribution of Mn(II) following exposure by IV
injection or inhalation.
Disclaimer
“This report was prepared as an account of work sponsored by an agency of the United States
Government. Neither the United States Government nor any agency thereof, nor any of their
employees, makes any warranty, express or limited, or assumes any legal liability or responsi-
bility for the accuracy, completeness, or usefulness of any information, apparatus, product, or
process disclosed, or represents that its use would not infringe privately owned rights. Refer-
ence herein to any specific commercial product, process, or service by trade name, trademark,
manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recom-
mendation, or favoring by the United States Government or any agency thereof. The views
and opinions of authors expressed herein do not necessarily state or reflect those of the United
States Government or any agency thereof.”
Supporting information
S1 Fig. PET/CT images and post-imaging, ex vivo biodistribution for two mice following
intravenous administration of 52Mn in aqueous solution. At 1 h p.i., 52Mn was observed in
the digestive tract, kidneys, and likely the pancreas. At 3 d p.i., 52Mn had cleared from the
digestive tract, while it is retained in the kidneys, as well as liver, pancreas, and thyroid gland.
Manganese-52 was eluted from the cation-exchange column in 0.067 M ammonium oxalate
solution. The ammonium oxalate product was heated to dryness, and then the heat was
increased to burn away the ammonium oxalate. Manganese-52 was resuspended by adding
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water followed by a drop of 6 M hydrochloric acid, then heated to dryness. Evaporation and
resuspension in water was repeated and then the 52Mn was finally resuspended in water,
resulting in a solution with pH of ~6.5. Mice (n = 2; C57-Black-6; male) were anesthetized by
isoflurane (1–2% induction), injected in the tail vein with ~41 μCi of 52Mn in 50 μL total vol-
ume, and imaged simultaneously side-by-side at 1 h and 3 d p.i. At the imaging timepoints,
anatomic images were obtained by non-contrast CT using an Inveon small animal PET/CT
scanner (Siemens Preclinical Solutions, Knoxville, Tennessee, United States), and PET data
were acquired using either the Inveon PET/CT scanner or a microPET Focus 220 scanner (Sie-
mens Preclinical Solutions). Static PET data were acquired for 30 minutes at the 1-hour time-
point and for 1 hour at the 3-day timepoint. Attenuation maps for each subject were obtained
from either the CT scan in the Inveon scanner or by a transmission scan on the Focus 220
scanner. Images were analyzed using Inveon Research Workplace software (Siemens Preclinical
Solutions).
(TIF)
S1 File. Data analysis of the cohorts of mice that received [52Mn]MnCl2 via IV injection.
This file is a workbook made using Microsoft Excel for Mac and contains multiple sheets.
(XLSX)
S2 File. Data analysis of the cohorts of mice that received [52Mn]MnCl2 via inhalation.
This file is a workbook made using Microsoft Excel for Mac and contains multiple sheets.
(XLSX)
S3 File. Comparison of results from IV injection and inhalation of [52Mn]MnCl2. This file
is a workbook made using Microsoft Excel for Mac and contains multiple sheets. The workbook
includes results from S1 File and S2 File, comparison of these results by plotting, and hypothe-
sis testing of these results by Student’s t-test with Welch’s correction at 1 d p.i. only.
(XLSX)
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